| 2020 |
Poteligeo® launched in Europe for the treatment for mycosis fungoides (MF) and Sézary syndrome (SS). |
| 2020 |
Crysvita® approved in the US for the treatment of tumor-induced osteomalacia (TIO). |
| 2021 |
New Vision toward 2030 designed to realize the creation and delivery of life-changing value. |
| 2021 |
Agreement reached with Amgen to jointly develop and commercialize KHK4083, a Kyowa Kirin-discovered anti-OX40 fully human monoclonal antibody. |
| 2021 |
Declared support for the recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD). |
| 2022 |
Global DE&I Statement adopted with 40% of global leaders to be female by 2030. |
| 2022 |
An automated injection device "G-Lasta® Subcutaneous Injection 3.6 mg BodyPod" launched in Japan for the long-acting G-CSF preparation, G-Lasta®. |
| 2022 |
Q-TOWER, the new biopharmaceutical analysis facility completed at Takasaki Plant, Kyowa Kirin's major biopharmaceutical manufacturing site. |
| 2023 |
PHOZEVEL® approved in Japan for the treatment of Hyperphosphatemia in chronic kidney disease patients. |
| 2023 |
Kyowa Kirin announced the acquisition of UK company Orchard Therapeutics with strength in hematopoietic stem cell gene therapy. |
| 2024 |
Lenmeldy™ , an innovative hematopoietic stem cell (HSC) gene therapy, approved and launched in the United States. |
| 2024 |
A new biologics manufacturing plant decided to be established in North Carolina, the United States. |
| 2024 |
A global strategic collaboration signed to develop and commercialize menin inhibitor ziftomenib in acute leukemias with Kura Oncology. |
| 2025 |
Completion of the HB7 Building, a new biopharmaceutical DS (Drug Substance) manufacturing facility at the Takasaki Plant, to strengthen global manufacturing capacity and talent development. |
| 2025 |
FDA approval and U.S. launch of KOMZIFTI™ (ziftomenib) for adult AML (Acute Myeloid Leukemia). |
